Enanta Pharmaceuticals, Inc

CONTACT

Lead Sponsor

Enanta Pharmaceuticals, Inc

Age

0 - 3 years

Sex

ALL

Healthy Volunteers

No

•Participants diagnosed with RSV infection using an approved diagnostic assay, without known and/or documented coinfection with SARS-CoV-2 or influenza
•Participant has signs of RSV infection with onset ≤3 days (72 hours) at the time of randomization
•In the Investigator's opinion, the participant's caregiver understands and is able to comply with protocol requirements, instructions, and restrictions, and the participant is likely to complete the study as planned. The caregiver(s) should be of legal age.

•Participant has any condition that in the opinion of the Investigator would interfere with the evaluation of the study drug or participant safety.
•Participant has underlying immune deficiency. Participants with immunoglobulin A deficiency are not excluded.
•Participant has had major surgery within 6 weeks prior to randomization or has major surgery planned during the course of the study.
•Participant is currently taking either chronically or has taken within 7 days prior to randomization, or is anticipated to receive during the course of the study, systemic medications that are known to cause immunosuppression other than corticosteroids for \>5 days.
•Participant has received an investigational agent within the last 30 days or 5 half-lives of the investigational agent, whichever is longer.

Related studies

NCT06160128 · COVID-19, SARS-CoV-2 Infection, RSV, and more

NCT06684743 · RSV

NCT07171164 · Older Adults Without Any Specific Clinical Condition, Social Networks, and more

NCT05045612 · Infectious Disease, Influenza, and more

NCT06998251 · Pneumococcal Infections, Respiratory Syncytial Virus (RSV) Infection, and more

A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus